Moderna, Inc. $MRNA Shares Newly Bought by DMC Group LLC

DMC Group LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,922 shares of the company’s stock, valued at approximately $563,000.

A number of other hedge funds have also made changes to their positions in MRNA. Western Pacific Wealth Management LP purchased a new position in Moderna during the third quarter valued at approximately $29,000. Allied Private Wealth LLC acquired a new position in Moderna in the 2nd quarter valued at approximately $30,000. Canton Hathaway LLC acquired a new position in Moderna in the 1st quarter valued at approximately $31,000. Archer Investment Corp purchased a new stake in Moderna in the 2nd quarter worth approximately $36,000. Finally, Ramsey Quantitative Systems purchased a new stake in Moderna in the 3rd quarter worth approximately $40,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

MRNA stock opened at $207.97 on Wednesday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $254.48. The firm has a 50 day moving average of $176.73 and a two-hundred day moving average of $83.73.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the company earned ($2.13) EPS. Research analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current year.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of research reports. Evercore lifted their target price on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. JPMorgan Chase & Co. upped their price target on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research note on Friday, August 21st. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 price target on the stock. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, Singular Research raised Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $107.10.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s Phase 3 INTerpath-001 trial showed that intismeran, combined with Keytruda, reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone. The regimen also reduced the risk of distant metastasis or death by 38%, and the results were accepted for publication in The New England Journal of Medicine. Moderna Phase 3 Melanoma Vaccine Validation
• Positive Sentiment: CEO Stéphane Bancel said Moderna’s mRNA platform could support cancer vaccines beyond melanoma, including additional tumor types. Management continues to present the technology as a scalable platform with significant long-term commercial potential. Moderna CEO on Cancer Vaccine Potential
• Neutral Sentiment: One price target for Moderna’s depositary receipt was raised 14.39% to ARS11,759.61, indicating that some analysts remain constructive despite the recent volatility. Moderna Depositary Receipt Price Target
• Negative Sentiment: William Blair downgraded MRNA from Outperform to Market Perform, citing valuation after a roughly 545% year-to-date rally. The downgrade added to profit-taking pressure and reinforced concerns that much of the cancer-vaccine success is already reflected in the stock. William Blair Downgrades Moderna
• Negative Sentiment: The 42% recurrence reduction was below investor hopes for a result closer to the approximately 49% benefit seen in Phase 2. Overall-survival data are not yet mature, while Moderna remains unprofitable and must commercialize an individualized, patient-specific manufacturing process. Merck and Moderna Cancer Vaccine Results

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the sale, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 197,251 shares of company stock valued at $33,875,904. Insiders own 10.80% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.